ArticleCureus2026
Palliative Stereotactic Body Radiotherapy for Metastatic Clear Cell Sarcoma: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell sarcoma (CCS) is an extremely rare malignancy. We report a case of metastatic CCS in which pain was successfully relieved with palliative stereotactic body radiotherapy (SBRT). The patient was a 57-year-old man diagnosed with CCS of the right heel five years prior. He had undergone seven surgical resections and chemotherapy (trabectedin and pazopanib) for the primary tumor and metastatic lesions. While receiving trabectedin therapy, he was referred to our facility for palliative radiotherapy. This was due to the rapid enlargement of a metastatic lesion in the right thigh. His symptom was pain in the right lower extremity. Metastatic lesions in the right thigh and right abdomen were targeted for SBRT. SBRT was delivered every other day using an O-ring linear accelerator (OXRAY) with 6-MV flattening filter-free beams, volumetric modulated arc therapy, and image-guided radiotherapy (IGRT) (thigh: treatment volume 319.57 mL, prescribed dose (the dose covering 95% of the target volume; D95) 30 Gy in 5 fractions, maximum dose 67.05 Gy, irradiation time 324 seconds/fraction, treatment duration 10 days; abdomen: treatment volume 36.2 mL, prescribed dose (D95) 36 Gy in 3 fractions, maximum dose 51.92 Gy, irradiation time 293 seconds/fraction, treatment duration five days). By the fifth day of SBRT, the pain in the right lower extremity completely resolved. Shrinkage of the right thigh metastasis was observed on cone-beam computed tomography (CT) scans of IGRT during the treatment period. CT imaging performed seven weeks after SBRT showed further shrinkage of both lesions. The pain did not recur until the patient died of renal failure two months after SBRT. No adverse events occurred during the clinical course. SBRT may be a viable palliative treatment option for CCS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.